title: Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.
abstract: OBJECTIVE
  To determine whether treatment with an autologous whole-cell vaccine modified with the hapten dinitrophenyl (DNP vaccine) is an effective postsurgical adjuvant treatment for melanoma patients with clinically evident nodal metastases.
  
  
  METHODS
  Eligible patients had regional nodal metastases that were large enough (> or = 3 cm diameter) to prepare vaccine. Following standard lymphadenectomy, patients were treated with DNP vaccine on a monthly or weekly schedule.
  
  
  RESULTS
  Of 62 patients with metastasis in a single lymph node bed (stage III), 36 are alive after a median follow-up time of 55 months (range, 29 to 76); the projected 5-year relapse-free and overall survival rates are 45% and 58%, respectively. Of 15 patients with metastases in two nodal sites, five are alive with a median follow-up time of 73 months. An unexpected finding was the significantly better survival of older patients; the projected 5-year survival of patients greater than 50 versus < or = 50 years was 71% and 47%, respectively (P = .011, log-rank test). The development of a positive delayed-type hypersensitivity (DTH) response to unmodified autologous melanoma cells was associated with significantly longer 5-year survival (71% v 49%; P = .031). Finally, the median survival time from date of first recurrence was significantly longer for patients whose subcutaneous recurrence exhibited an inflammatory response (> 19.4 v 5.9 months; P < .001).
  
  
  CONCLUSIONS
  Postsurgical adjuvant therapy with autologous DNP-modified vaccine appears to produce survival rates that are markedly higher than have been reported with surgery alone. Moreover, this approach has some intriguing immunobiologic features that might provide insights into the human tumor-host relationship.
authors.affiliation: Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA. d_berd@lac.jci.tju.edu
authors.forename: D
authors.initials: D
authors.lastname: Berd
authors.forename: H C
authors.initials: HC
authors.lastname: Maguire
authors.forename: L M
authors.initials: LM
authors.lastname: Schuchter
authors.forename: R
authors.initials: R
authors.lastname: Hamilton
authors.forename: W W
authors.initials: WW
authors.lastname: Hauck
authors.forename: T
authors.initials: T
authors.lastname: Sato
authors.forename: M J
authors.initials: MJ
authors.lastname: Mastrangelo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006241:Haptens / Q000008:administration & dosage; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D011184:Postoperative Period; D011379:Prognosis; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016019:Survival Analysis
chemical_list: D018906:Antineoplastic Agents, Alkylating; D019496:Cancer Vaccines; D006241:Haptens; D003520:Cyclophosphamide